A Phase IV Study to Assess the Efficacy and Safety of Dapagliflozin Compared With Acarbose in Drug-Naive Patients With T2DM in China

Condition:   Type 2 Diabetes Mellitus Intervention:   Drug: Dapagliflozin/Acarbose Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials